BIXLENVO (Bictegravir Sodium; Lenacapavir Sodium) Patent Expiration, LOE Window & CMS Spending
BIXLENVO (Bictegravir Sodium; Lenacapavir Sodium) by Gilead Sciences: FDA Orange Book core substance LOE 2038-08-16, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $4,595 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N221104 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-08-16 |
| Last Listed Patent or Exclusivity Date | 2038-08-16 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($4,595 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.